A phase 1B/2 trial of avelumab and pepinemab as second line for metastatic pancreatic adenocarcinoma

L.I. Ruffolo,K.M. Jackson,N.A. Ullman,P.R. Burchard, M. Georger, R. Jewell,B.A. Belt,R.C. Fields, D. Mulkerin,E.E. Evans,T.L. Fisher,M. Zauderer, J. Yeh,D.C. Linehan

HPB（2023）

引用 0|浏览2

暂无评分

摘要

Background: Semaphorin 4D (Sema4D) is an immunomodulatory glycoprotein highly expressed on the surface of tumor infiltrating lymphocytes. Our preclinical work has demonstrated targeting Sema4D sensitizes murine models of PDAC to Immune checkpoint blockade. Here we present a Phase 1b/2 trial translating this novel therapeutic target.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要